A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Completed · Phase 2 · NCT04640077
Conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
At a glance
- Research payments reported, 2025
- $126
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 95
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- No Intervention (other), donanemab (drug)
- Dates
- Started 2020-11-23; completion 2024-02-27
- Results posted
- Yes
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing
From ClinicalTrials.gov, last updated 2025-06-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $126 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Irvine Center for Clinical Research Inc $126
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.